Muhammad Usman Qamar1,2, Sidrah Saleem1, Mark Alexander Toleman3, Muhammad Saqalein2, Muhammad Waseem2, Muhammad Atif Nisar2, Mohsin Khurshid2,4, Zeeshan Taj2, Shah Jahan5. 1. Department of Microbiology, University of Health Sciences, Lahore, Pakistan. 2. Department of Microbiology, Faculty of Life Sciences, Government College University Faisalabad, Pakistan. 3. School of Medicine & Infectious Disease, University Hospital of Wales, Heath Park, Cardiff University, Cardiff, United Kingdom. 4. College of Allied Health Professionals, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan. 5. Department of Immunology, University of Health Sciences, Lahore, Pakistan.
Abstract
AIM: To determine the therapeutic potential of Manuka honey against New Delhi metallo-β-lactamase-1-producing Klebsiella pneumoniae ST11 in vitro and in vivo. MATERIALS & METHODS: Carbapenamases and metallo-β-lactamases-producing K. pneumoniae ST11 isolated from blood culture was confirmed by VITEK-2® system, matrix-assisted laser desorption ionization-time of flight and multilocus sequence typing, followed by determination of minimum inhibitory concentration (μg/ml) using VITEK-2 system. Genetic analysis of bla NDM-1 was done by PCR, pulsed-field gel electrophoresis and DNA hybridization. In vitro and in vivo efficacy of Manuka honey was performed by microbroth dilution assay and BALB/c mice model respectively. RESULTS: K. pneumoniae ST11 displayed resistance to commonly used antibiotics. bla NDM-1 was located on 150 and 270kb plasmids. Minimum inhibitory concentration and minimum bactericidal concentration of Manuka honey was 30% (v/v) and substantial reduction of bacterial mean log value (>1 log) was observed in mice. Histological analysis of mice liver and kidneys demonstrated mild to moderate inflammation. CONCLUSION: Manuka honey can be used as an alternate therapeutic approach for management of New Delhi metallo-β-lactamase-producing pathogens.
AIM: To determine the therapeutic potential of Manuka honey against New Delhi metallo-β-lactamase-1-producing Klebsiella pneumoniae ST11 in vitro and in vivo. MATERIALS & METHODS: Carbapenamases and metallo-β-lactamases-producing K. pneumoniae ST11 isolated from blood culture was confirmed by VITEK-2® system, matrix-assisted laser desorption ionization-time of flight and multilocus sequence typing, followed by determination of minimum inhibitory concentration (μg/ml) using VITEK-2 system. Genetic analysis of bla NDM-1 was done by PCR, pulsed-field gel electrophoresis and DNA hybridization. In vitro and in vivo efficacy of Manuka honey was performed by microbroth dilution assay and BALB/c mice model respectively. RESULTS:K. pneumoniae ST11 displayed resistance to commonly used antibiotics. bla NDM-1 was located on 150 and 270kb plasmids. Minimum inhibitory concentration and minimum bactericidal concentration of Manuka honey was 30% (v/v) and substantial reduction of bacterial mean log value (>1 log) was observed in mice. Histological analysis of mice liver and kidneys demonstrated mild to moderate inflammation. CONCLUSION:Manuka honey can be used as an alternate therapeutic approach for management of New Delhi metallo-β-lactamase-producing pathogens.
Authors: Muhammad Usman Qamar; Timothy R Walsh; Mark A Toleman; Sidrah Saleem; Shah Jahan Journal: Braz J Microbiol Date: 2018-04-12 Impact factor: 2.476